Active ingredient: Guanfacine (as HCl) 1 mg, 2 mg, 3 mg, 4 mg; extended-release tabs. Indication: Attention- deficit hyperactivity disorder (ADHD) in patients aged 6-17 years. Clinical trials: The ...

Two treatments for children with attention-deficit hyperactivity disorder (ADHD) have been recommended by the European Medicines Agency (EMA) to receive marketing authorizations. The agency's ...

Shire’s experimental drug to treat attention-deficit hyperactive disorder showed positive results in a recent study, bringing the company one step closer to earning approval from the Food and Drug ...

LONDON (Reuters) - U.S. regulators approved Shire's extended-release hyperactivity drug Intuniv and the product is expected to be available in U.S. pharmacies in November, the company said on Thursday ...